Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Cancer Science|June 9, 2012
Randomized phase II study of three doses of oral TAS-108 in postmenopausal patients with metastatic breast cancerHideo Inaji, Hiroji Iwata, Takahiro Nakayama, et al.
Cancers|August 27, 2021
Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)Eriko Tokunaga, Norikazu Masuda, Naohito Yamamoto, et al.
International Journal of Clinical Oncology|February 11, 2015
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patientsHiroyasu Yamshiro, Hiroji Iwata, Norikazu Masuda, et al.
Cancer Science|March 4, 2017
Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancerKenji Tamura, Kenichi Inoue, Norikazu Masuda, et al.
International Journal of Radiation Oncology, Biology, Physics|September 25, 2007
Haplotype-based analysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patientsTomo Suga, Atsuko Ishikawa, Masakazu Kohda, et al.
Breast Cancer : Basic and Clinical Research|July 18, 2018
Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational StudyHiroyasu Yamashiro, Masataka Sawaki, Norikazu Masuda, et al.
Breast Cancer (Tokyo, Japan)|June 24, 2026
Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trialTakashi Yamanaka, Joohyuk Sohn, Kazuki Sudo, et al.
NPJ Breast Cancer|August 22, 2024
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancerEmi Noguchi, Takashi Yamanaka, Hirofumi Mukai, et al.
Pageof 6